(Q54373171)

English

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.

scientific article published on 5 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

George Fountzilas

23

object named as

George Fountzilas

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Dimitrios Pectasides

22

object named as

Dimitrios Pectasides

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

George Kouvatseas

5

object named as

George Kouvatseas

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Evangelia Razis

1

object named as

Evangelia Razis

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Dimitrios Bafaloukos

18

object named as

Dimitrios Bafaloukos

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Epaminontas Samantas

11

object named as

Epaminontas Samantas

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

George Pentheroudakis

2

object named as

George Pentheroudakis

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Pavlos Papakostas

8

object named as

Pavlos Papakostas

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Konstantine T Kalogeras

21

object named as

Konstantine T Kalogeras

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

16

object named as

Amanda Psyrri

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Ioannis Efstratiou

14

object named as

Ioannis Efstratiou

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Eleftheria Tsolaki

15

object named as

Eleftheria Tsolaki

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

10

object named as

Anna Goussia

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

author name string

George Rigakos

3

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Olympia Tzaida

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Thomas Makatsoris

7

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Maria Bai

9

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Demetrios Papamichael

12

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Ourania Romanidou

13

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Wendy De Roock

17

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

George Klouvas

19

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Sabine Tejpar

20

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

publication date

5 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

140

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

737-748

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

https://scigraph.springernature.com/pub.10.1007/s00432-014-1626-2

0 references

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

A colorectal cancer classification system that associates cellular phenotype and responses to therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Molecular determinants of cetuximab efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1626-2

21 January 2018

Epidermal growth factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24595598

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/24595598

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24595598

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24595598

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24595598

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-014-1626-2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24595598

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54373171&oldid=1835181468"